Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cyclacel Pharmaceuti (NQ: CYCC )

0.6269 -0.0221 (-3.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cyclacel Pharmaceuti

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Is Coursera (COUR) Stock Down 16% Today?
Coursera stock is falling on Tuesday as COUR investors react to the company's lackluster guidance in its latest earnings report. 
Via InvestorPlace
Why Is Medifast (MED) Stock Down 20% Today?
Medifast stock is down on Tuesday after the company released mixed results for Q1 2024 alongside a weak outlook for Q2 2024. 
Via InvestorPlace
Earnings Outlook For Cyclacel Pharmaceuticals
Via Benzinga
Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why GeneDx Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is Greenwave Technology Solutions (GWAV) Stock Up 15% Today?
Greenwave Technology Solutions stock is up on Tuesday alongside heavy trading of GWAV shares despite a lack of news from the company. 
Via InvestorPlace
Why Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?
Cyclacel Pharmaceuticals stock is up on Tuesday with heavy trading of CYCC shares after the company withdrew a public offering. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Our coverage for Tuesday starts with a dive into the biggest pre-market stock movers traders will want to keep an eye on today! 
Via InvestorPlace
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
From Cyclacel
Via GlobeNewswire
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Philips Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
From Cyclacel
Via GlobeNewswire
CYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023
CYCC stock results show that Cyclacel Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
Earnings Scheduled For March 19, 2024
Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per share on revenue of $931.97 million. 
Via Benzinga
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma 
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
From Cyclacel
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.